Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis. 2019

Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Reliable biomarkers associated with disability worsening in multiple sclerosis (MS) are still needed. To determine a possible association of intrathecal IgG synthesis and early disability worsening as measured by Expanded Disability Status Scale (EDSS) scoring in patients with relapsing-remitting MS or clinically isolated syndrome. Cerebrospinal fluid measurements and clinical data from the observational longitudinal German national multiple sclerosis cohort were analyzed. Patients were recruited between August 2010 and November 2015 from 18 centers. Data analysis was completed from August 2018 to December 2018. Patients were offered standard immunotherapies per national treatment guidelines. A possible association between intrathecal IgG synthesis and risk of EDSS worsening 4 years after study inclusion was tested as the primary end point by multivariable binomial regression analysis. Kaplan-Meier analysis with a log-rank test was used to assess the association of intrathecal IgG synthesis with the time to EDSS worsening. Associations between intrathecal IgM or IgA synthesis and other cerebrospinal fluid parameters and EDSS worsening were analyzed as exploratory end points. Data collection began before the hypotheses were formulated. Of all 1376 patients in the German Competence Network of Multiple Sclerosis cohort, 703 patients were excluded owing to missing cerebrospinal fluid or EDSS data. Of the 673 included patients, 459 (68.2%) were women. The mean (SD) age at baseline was 34 (10) years. Intrathecal IgG synthesis was associated with a higher risk of EDSS worsening after 4 years (odds ratio, 2.02 [95% CI, 1.15-3.58]; P = .01), independent of the occurrence of relapses and disease-modifying therapy. Additionally, intrathecal IgG synthesis was associated with earlier EDSS worsening; 4 years after study entry, worsening occurred in 28.4% (95% CI, 22.7%-34.1%) and 18.1% (95% CI, 12.4%-23.9%) of patients with and without intrathecal IgG synthesis, respectively. No association of other routine cerebrospinal fluid parameters with EDSS worsening was found. Patients with new diagnoses of relapsing-remitting multiple sclerosis or clinically isolated syndrome with intrathecal IgG synthesis had a higher risk of and shorter time to EDSS worsening across a 4-year period of follow-up. Intrathecal IgG synthesis is a potentially useful marker for disability worsening in patients with multiple sclerosis and may be useful for early treatment decisions.

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003711 Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system. Clinically Isolated CNS Demyelinating Syndrome,Clinically Isolated Syndrome, CNS Demyelinating,Demyelinating Disorders,Demyelination,Demyelinating Disease,Demyelinating Disorder,Demyelinations
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
September 2015, Multiple sclerosis (Houndmills, Basingstoke, England),
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
January 2006, Neuroimmunomodulation,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
September 1998, Acta neurologica Scandinavica,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
April 2021, Neurology,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
January 1992, European neurology,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
October 2020, Multiple sclerosis and related disorders,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
May 2016, Journal of neurology,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
January 2022, Frontiers in immunology,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
April 2020, Journal of neurology,
Christiane Gasperi, and Anke Salmen, and Gisela Antony, and Antonios Bayas, and Christoph Heesen, and Tania Kümpfel, and Ralf A Linker, and Friedemann Paul, and Martin Stangel, and Björn Tackenberg, and Florian Then Bergh, and Clemens Warnke, and Frank Weber, and Heinz Wiendl, and Brigitte Wildemann, and Uwe K Zettl, and Ulf Ziemann, and Frauke Zipp, and Hayrettin Tumani, and Ralf Gold, and Bernhard Hemmer, and
August 2015, Journal of neuroimmunology,
Copied contents to your clipboard!